Literature DB >> 8424733

Effects of scopolamine on autonomic profiles underlying motion sickness susceptibility.

S H Uijtdehaage1, R M Stern, K L Koch.   

Abstract

The purpose of this study was to examine the effects of scopolamine on the physiological patterns occurring prior to and during motion sickness stimulation. In addition, the use of physiological profiles in the prediction of motion sickness was evaluated. Sixty subjects ingested either 0.6 mg scopolamine, 2.5 mg methscopolamine, or a placebo. Heart rate (HR), respiratory sinus arrhythmia (an index of vagal tone), and electrogastrograms were measured prior to and during the exposure to a rotating optokinetic drum. Compared to the other groups, the scopolamine group reported fewer motion sickness symptoms, and displayed lower HR, higher vagal tone, enhanced normal gastric myoelectric activity, and depressed gastric dysrhythmias before and during motion sickness induction. Distinct physiological profiles prior to drum rotation could reliably differentiate individuals who would develop gastric discomfort from those who would not. Symptom-free subjects were characterized by high levels of vagal tone and low HR across conditions, and by maintaining normal (3 cpm) electrogastrographic activity during drum rotation. It was concluded that scopolamine offered motion sickness protection by initiating a pattern of increased vagal tone and gastric myoelectric stability.

Entities:  

Keywords:  NASA Discipline Neuroscience; NASA Discipline Number 16-10; NASA Program Space Physiology and Countermeasures; Non-NASA Center

Mesh:

Substances:

Year:  1993        PMID: 8424733

Source DB:  PubMed          Journal:  Aviat Space Environ Med        ISSN: 0095-6562


  10 in total

1.  Gastric myoelectrical and autonomic cardiac reactivity to laboratory stressors.

Authors:  P J Gianaros; K S Quigley; J T Mordkoff; R M Stern
Journal:  Psychophysiology       Date:  2001-07       Impact factor: 4.016

2.  Relationship between temporal changes in cardiac parasympathetic activity and motion sickness severity.

Authors:  Peter J Gianaros; Karen S Quigley; Eric R Muth; Max E Levine; Raymond C Vasko; Robert M Stern
Journal:  Psychophysiology       Date:  2003-01       Impact factor: 4.016

3.  Experimental gastric dysrhythmias and its correlation with in vivo gastric muscle contractions.

Authors:  Jinhong Xing; Liwei Qian; Jiande Chen
Journal:  World J Gastroenterol       Date:  2006-07-07       Impact factor: 5.742

Review 4.  Scopolamine (hyoscine) for preventing and treating motion sickness.

Authors:  Anneliese Spinks; Jason Wasiak
Journal:  Cochrane Database Syst Rev       Date:  2011-06-15

Review 5.  Sickness and satiety: physiological mechanisms underlying perceptions of nausea and stomach fullness.

Authors:  Max E Levine
Journal:  Curr Gastroenterol Rep       Date:  2005-08

6.  Effects of vection-induced motion sickness on gastric myoelectric activity and oral-cecal transit time.

Authors:  E R Muth; R M Stern; K L Koch
Journal:  Dig Dis Sci       Date:  1996-02       Impact factor: 3.199

7.  Effect of neurovestibular stimulation on autonomic regulation.

Authors:  F Costa; P Lavin; D Robertson; I Biaggioni
Journal:  Clin Auton Res       Date:  1995-10       Impact factor: 4.435

8.  Recent progress in gastric arrhythmia: pathophysiology, clinical significance and future horizons.

Authors:  Gregory O'Grady; Tim H-H Wang; Peng Du; Tim Angeli; Wim J E P Lammers; Leo K Cheng
Journal:  Clin Exp Pharmacol Physiol       Date:  2014-10       Impact factor: 2.557

9.  Load Dependency of Postural Control--Kinematic and Neuromuscular Changes in Response to over and under Load Conditions.

Authors:  Ramona Ritzmann; Kathrin Freyler; Elmar Weltin; Anne Krause; Albert Gollhofer
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

10.  Characterizing the Access of Cholinergic Antagonists to Efferent Synapses in the Inner Ear.

Authors:  Choongheon Lee; Anjali K Sinha; Kenneth Henry; Anqi W Walbaum; Peter A Crooks; Joseph C Holt
Journal:  Front Neurosci       Date:  2021-12-14       Impact factor: 4.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.